Literature DB >> 10435490

Penicillamine should not be used as initial therapy in Wilson's disease.

G J Brewer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10435490     DOI： 10.1002/1531-8257(199907)14:4<551::aid-mds1002>3.0.co;2-s

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  9 in total

Review 1.  Wilson disease-treatment perspectives.

Authors:  Tomasz Litwin; Karolina Dzieżyc; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

2.  Imaging and Clinical Worsening After Penicillamine Treatment in Wilson's Disease.

Authors:  Hélio A G Teive; Arnolfo de Carvalho; Renato P Munhoz; Adriana Moro; Mariana Moscovich; Egberto Reis Barbosa
Journal:  Mov Disord Clin Pract       Date:  2015-08-16

Review 3.  Diagnosis and treatment of Wilson's disease.

Authors:  Indu Subramanian; Zeba F Vanek; Jeff M Bronstein
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 4.  Advances in Treatment of Wilson Disease.

Authors:  Annu Aggarwal; Mohit Bhatt
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-02-28

5.  DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease.

Authors:  Navasona Krishnan; Christy Felice; Keith Rivera; Darryl J Pappin; Nicholas K Tonks
Journal:  Genes Dev       Date:  2018-06-26       Impact factor: 12.890

6.  Clinical and Genetic Analysis in Neurological Wilson's Disease Patients With Neurological Worsening Following Chelator Therapy.

Authors:  Haiman Hou; Dingbang Chen; Junxiu Liu; Li Feng; Jiwei Zhang; Xiuling Liang; Yuming Xu; Xunhua Li
Journal:  Front Genet       Date:  2022-04-04       Impact factor: 4.772

Review 7.  The Role of Zinc in the Treatment of Wilson's Disease.

Authors:  Abolfazl Avan; Anna Członkowska; Susan Gaskin; Alberto Granzotto; Stefano L Sensi; Tjaard U Hoogenraad
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

8.  Long-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson's disease in children.

Authors:  Hong Chang; Aijing Xu; Zhihong Chen; Ying Zhang; Fei Tian; Tang Li
Journal:  Exp Ther Med       Date:  2013-02-22       Impact factor: 2.447

9.  Advance in the pathogenesis and treatment of Wilson disease.

Authors:  Qin-Yun Dong; Zhi-Ying Wu
Journal:  Transl Neurodegener       Date:  2012-11-27       Impact factor: 8.014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.